Epigenetic Silencing and Resistance to Imatinib Mesylate in CML

Abstract

We performed analyses of DNA methylation data reported in the final report with clinical outcome of CML patients. DNA methylation significantly correlated with survival. CML patients with average methylation zscore values above zero had significantly shorter survival than patients with z-scores below zero (median 10 months vs 59 months, P<0.0001). This was true also within CP (median survival of 44 months for patients with high methylation vs median not reached in patients with low methylation, P=0.02) and AP (median survival of 11 months for patients with high methylation vs 27 months in patients with low methylation, P=0.009). Changes in gene silencing by DNA methylation may play a role in developing alternative routes for cells to circumvent the effects of imatinib.

Open PDF

Document Details

Document Type
Technical Report
Publication Date
Jul 01, 2007
Accession Number
ADA474866

Entities

People

  • Jean-pierre Issa

Organizations

  • The University of Texas MD Anderson Cancer Center

Tags

Communities of Interest

  • Biomedical

DTIC Thesaurus Topics

  • Biomedical Research
  • Blood Cells
  • Cancer
  • Cells
  • Clinical Trials
  • Department Of Defense
  • Disease Attributes
  • Diseases And Disorders
  • Electronic Mail
  • Hematologic Diseases
  • Information Operations
  • Leukemia
  • Medical Personnel
  • Methylation
  • Neoplasms
  • Resistance
  • Survival

Readers

  • Breast cancer cell signaling and growth regulation.
  • Molecular and genetic basis of cancer.
  • Regression Analysis.